Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70370 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo‐Controlled, Double‐Blind Treatment Trial Britta S. Bürker Kristine V. Brautaset Englund Charlotte Myrdal Østby Stein Andersson Lars Gullestad Kaspar Broch Clinical Transplantation ABSTRACT Background Cognitive dysfunction after successful heart transplantation (HTx) is not uncommon. Lower hemoglobin levels have previously been associated with cognitive dysfunction in heart transplant recipients (HTx recipients). In a randomized, placebo‐controlled, double‐blind treatment trial, we assessed as a pre‐specified secondary outcome whether a single intravenous iron supplement for iron deficiency in HTx recipients resulted in changes in cognitive function after 6 months. Methods In the “Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients” (IronIC) trial, we assessed cognitive function at baseline and at 6‐month follow‐up with the following tests of the Cambridge Neuropsychological Test Automated Battery: Reaction Time, Paired Associates Learning, and Spatial Working Memory. Of 94 participants with cognitive data at baseline and follow‐up, 49 were randomized to the single intravenous iron supplement, while 45 received placebo. Results Raw score changes from baseline to follow‐up did not differ statistically significantly between study groups (two measures of each test analyzed). In the total sample, 27%–44% of participants performed at baseline at least one standard deviation below the normative mean on measures of memory and working memory/executive functions. Exploratory analyses indicated that performance on measures of memory might decrease more than expected with increasing age. Conclusion A single intravenous iron supplement for iron deficiency in HTx recipients did not result in statistically significant cognitive changes after 6 months. The group as a whole performed approximately half a standard deviation below the normative mean on measures of memory and working memory/executive functions. Regular cognitive screening after HTx is recommended. Clinical Trial Registration Trial Registration: ClinicalTrials.gov identifier: NCT03662789 10.1111/ctr.70370 http://onlinelibrary.wiley.com/termsAndConditions#vor